Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC cut its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 44.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,940 shares of the company's stock after selling 20,830 shares during the period. Voya Investment Management LLC's holdings in Structure Therapeutics were worth $703,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in GPCR. ANTIPODES PARTNERS Ltd boosted its position in Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after acquiring an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in Structure Therapeutics during the 4th quarter worth approximately $40,000. Assetmark Inc. grew its position in Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after purchasing an additional 953 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Structure Therapeutics by 673.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock worth $111,000 after purchasing an additional 3,549 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Trading Down 7.2%

GPCR traded down $1.72 during midday trading on Wednesday, hitting $22.17. 474,542 shares of the company traded hands, compared to its average volume of 927,844. The business has a 50 day simple moving average of $20.98 and a two-hundred day simple moving average of $26.75. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of -29.96 and a beta of -1.69. Structure Therapeutics Inc. has a 52-week low of $13.22 and a 52-week high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Equities research analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on GPCR shares. Citigroup started coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. HC Wainwright lowered their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday. Finally, William Blair assumed coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics presently has an average rating of "Buy" and a consensus target price of $78.00.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.